Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Subhas Balaram Bhowmick"'
Publikováno v:
Expert Opinion on Drug Delivery. 16:1287-1311
Introduction: The delivery of drug payload to treat various brain diseases are met with various hindrances owing to the presence of the homeostasis regulatory gate, Blood-Brain Barrier (BBB). Altho...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85947814a1fc17581d0d7bfb2897a643
https://doi.org/10.1080/17425247.2019.1676721
https://doi.org/10.1080/17425247.2019.1676721
Autor:
Vivek Patel, Subhas Balaram Bhowmick, Rohan Lalani, Shubhadeep Banerjee, Denish Bardoliwala, Saikat Ghosh, Kuntal Maiti, Ambikanandan Misra
Publikováno v:
Journal of Controlled Release. 296:114-139
Hematological cancers are a group of malignancies affecting human hematopoietic and lymphoid tissues. Although the patients respond to treatment regimen during initial phases, the hematoma tumor heterogeneity results in the presence of some minimal d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0797eea0e49815c01d2c72149f0c3578
https://doi.org/10.1016/j.jconrel.2019.01.011
https://doi.org/10.1016/j.jconrel.2019.01.011
Autor:
Krutika K. Sawant, Subhas Balaram Bhowmick, Ankit Javia, A. J. Khopade, Shubhadeep Banerjee, Kuntal Maiti, Ambikanandan Misra, Saritha Shetty, Saikat Ghosh, Denish Bardoliwala
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 337
Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic components of progesterone receptor, HER2/neu and estrogen receptor in breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::804af416674cb1ece149745f19faa6ee
https://pubmed.ncbi.nlm.nih.gov/34273417
https://pubmed.ncbi.nlm.nih.gov/34273417
Autor:
Anjali Pathak, Subhas Balaram Bhowmick, Saikat Ghosh, Ambikanandan Misra, Amit Dabke, Pooja Mishra
Publikováno v:
Applications of Polymers in Drug Delivery ISBN: 9780128196595
The delivery of active drug substance for effective amelioration of various disorders has been holistically limited through the presence of various physicochemical barriers characteristics of the disease conditions. One of the major detrimental reaso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9973aad4fecad8dc8a439703ddbf8d41
https://doi.org/10.1016/b978-0-12-819659-5.00014-8
https://doi.org/10.1016/b978-0-12-819659-5.00014-8
Autor:
Saikat Ghosh, Rohan Lalani, Shubhadeep Banerjee, Vivek Patel, Subhas Balaram Bhowmick, Kuntal Maiti, Ambikanandan Misra
Publikováno v:
Nanomedicine (London, England). 15(26)
Aim: To improve the efficacy of poly-ethylene glycol (PEG)ylated liposomes coloaded with doxorubicin and vincristine against triple-negative breast cancer (TNBC) and non-small-cell lung cancer (NSCLC). Methods: The combinatorial index of the drugs wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee2e961f0a9557552da0e4616f860f7
https://pubmed.ncbi.nlm.nih.gov/33090073
https://pubmed.ncbi.nlm.nih.gov/33090073
Autor:
Swati Biswas, Saikat Ghosh, Kuntal Maiti, Himanshu Bhatt, Shubhadeep Banerjee, Rohan Lalani, Subhas Balaram Bhowmick, Yamini Bobde, Ambikanandan Misra, Vivek Patel
Publikováno v:
Nanomedicine : nanotechnology, biology, and medicine. 31
The current work aims to explore the biological characteristics of vincristine synergistic co-loading into pegylated liposomal doxorubicin in non-indicated modalities of non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC). The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287bd5a9b5240169d8e1cbbef055e813
https://pubmed.ncbi.nlm.nih.gov/33075540
https://pubmed.ncbi.nlm.nih.gov/33075540
Autor:
Thennati Rajamannar, Shravanti Bhowmik, Kuntal Maiti, Deepak Jain, Amaresh Chakra, Subhas Balaram Bhowmick, Pradeep Shahi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:521-532
To compare the pharmacokinetic bioequivalence and safety of a generic pegylated liposomal doxorubicin formulation (SPIL DXR hydrochloride liposome injection) with that of the reference products, Caelyx or Doxil. Two open-label, two-way reference cros
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed519171ae018e1c4a37ab8ea098b20b
https://doi.org/10.1007/s00280-018-3643-3
https://doi.org/10.1007/s00280-018-3643-3
Autor:
Chantal M. Wallenwein, Tatyana Kovshova, Jia Ning Nicolette Yau, Matthias G. Wacker, Kuntal Maiti, Shakti Nagpal, Yi Hsuan Ou, Subhas Balaram Bhowmick, Svetlana Gelperina, Giorgia Pastorin, Julian Knoll, Daniel Juncheng Fang, Harshvardhan Modh
Publikováno v:
International Journal of Pharmaceutics. 608:121073
A growing number of nanomedicines entered the clinical trials and improved our understanding of the in vivo responses expected in humans. The in vitro drug release represents an important critical quality attribute involved in pharmacokinetics. Estab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820c7348a4c5d4081d7fcc03da11f315
https://doi.org/10.1016/j.ijpharm.2021.121073
https://doi.org/10.1016/j.ijpharm.2021.121073
Autor:
Kuntal Maiti, Thennati Rajamannar, Pradeep Shahi, Shravanti Bhowmik, Amaresh Chakra, Subhas Balaram Bhowmick
Publikováno v:
Leukemia & Lymphoma. 59:1478-1481
The adjuvant use of liposomal doxorubicin (DXR) remains a well-documented treatment for multiple myeloma [1,2] and has demonstrated a beneficial therapeutic effect (in terms of overall response rat...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d89fb518ea529cbecd31be1af4143915
https://doi.org/10.1080/10428194.2017.1382692
https://doi.org/10.1080/10428194.2017.1382692
Autor:
Subhas Balaram Bhowmick, Deepak Jain, Vinod Burade, Thennati Rajamannar, Kuntal Maiti, Rishit Zalawadia
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:899-913
The liposomal formulation of doxorubicin [doxorubicin (DXR) hydrochloride (HCl) liposome injection, Caelyx®] alters the tissue distribution of DXR as compared with nonliposomal DXR, resulting in an improved benefit-risk profile. We conducted studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a236ace4ed203a454598f2b07027c3a
https://doi.org/10.1007/s00280-017-3278-9
https://doi.org/10.1007/s00280-017-3278-9